In This Story GOOGL -0.14% LLY -0.58% NVS +1.14% Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google ( GOOGL -0.14% ) executive. Suggested Reading Here’s how much the Best Picture nominees grossed at the box office Apple faces a 'fork in the road year,' analysts say Some Walmart managers can now make more than $600,000 Inside Barron Trump’s high-end real estate ambitions with

Tag-uri: Real Estate